Literature DB >> 21185401

The impact of cardiac resynchronization therapy on the incidence of ventricular arrhythmias in mild heart failure.

Michael R Gold1, Cecilia Linde, William T Abraham, Ajmal Gardiwal, Jean-Claude Daubert.   

Abstract

BACKGROUND: Cardiac resynchronization therapy (CRT) decreases mortality, improves functional status, and induces reverse left ventricular (LV) remodeling in selected populations. However, the effect of CRT on ventricular arrhythmias is controversial. This is particularly important among patients with mild heart failure (HF), in whom sudden death is a leading cause of mortality.
OBJECTIVE: This study sought to assess the impact of CRT on ventricular arrhythmias in mild HF.
METHODS: The REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study is a multicenter randomized, double-blind trial of CRT among patients with mild systolic HF. The time to first appropriate, treated ventricular tachycardia/ventricular fibrillation (VT/VF) episode or spontaneous sustained VT in cardiac resynchronization therapy plus defibrillation device (CRT-D) patients was compared between groups, as were predictors of VT/VF.
RESULTS: The study randomized 508 patients who received CRT-D devices. There were no significant demographic differences between groups. There were no differences in VT/VF episodes or VT storm between groups. Specifically, in the CRT ON group, the estimated event rate was 18.7% at 2 years, compared with 21.9% in the CRT OFF group (hazard ratio 1.05, P = .84). However, among CRT ON patients, those with reverse remodeling had a reduced incidence of VT/VF compared with those without remodeling (5.6% vs. 16.3%, hazard ratio 0.31, P = .001).
CONCLUSION: CRT for up to 2 years does not impact VT/VF in mild HF despite marked clinical and remodeling effects of pacing. This neutral effect may be attributable to competing antiarrhythmic effects of reverse remodeling and proarrhythmic effect of pacing. CLINICAL TRIAL REGISTRATION: http://www.clinicaltrials.gov/ct2/show/NCT00271154.
Copyright © 2011 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21185401     DOI: 10.1016/j.hrthm.2010.12.031

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  16 in total

1.  Predictors and long-term outcome of super-responders to cardiac resynchronization therapy.

Authors:  Abdul Ghani; Peter Paul H M Delnoy; Ahmet Adiyaman; Jan Paul Ottervanger; Anand R Ramdat Misier; Jaap Jan J Smit; Arif Elvan
Journal:  Clin Cardiol       Date:  2017-03-14       Impact factor: 2.882

2.  Outcome of super-responders to cardiac resynchronization therapy defined by endpoint-derived parameters of left ventricular remodeling: a two-center retrospective study.

Authors:  David Hürlimann; Susann Schmidt; Burkhardt Seifert; Ardan M Saguner; Gerhard Hindricks; Thomas F Lüscher; Frank Ruschitzka; Jan Steffel
Journal:  Clin Res Cardiol       Date:  2014-10-10       Impact factor: 5.460

3.  Predictors of sustained ventricular arrhythmias in cardiac resynchronization therapy.

Authors:  Daniel J Friedman; Robert K Altman; Mary Orencole; Michael H Picard; Jeremy N Ruskin; Jagmeet P Singh; E Kevin Heist
Journal:  Circ Arrhythm Electrophysiol       Date:  2012-07-11

4.  The evaluation of non-ischemic dilated cardiomyopathy with T1 mapping and ECV methods using 3T cardiac MRI.

Authors:  Cemile Ayşe Görmeli; Zeynep Maraş Özdemir; Ayşegül Sağır Kahraman; Jülide Yağmur; Ramazan Özdemir; Cemil Çolak
Journal:  Radiol Med       Date:  2016-10-27       Impact factor: 3.469

5.  The effect of reverse remodeling on long-term survival in mildly symptomatic patients with heart failure receiving cardiac resynchronization therapy: results of the REVERSE study.

Authors:  Michael R Gold; Claude Daubert; William T Abraham; Stefano Ghio; Martin St John Sutton; John Harrison Hudnall; Jeffrey Cerkvenik; Cecilia Linde
Journal:  Heart Rhythm       Date:  2014-11-15       Impact factor: 6.343

6.  Electrical devices for left ventricular dysfunction and heart failure: do we need revised guidelines?

Authors:  Maya Guglin; S Serge Barold
Journal:  J Interv Card Electrophysiol       Date:  2011-12-17       Impact factor: 1.900

Review 7.  Devices in the management of advanced, chronic heart failure.

Authors:  William T Abraham; Sakima A Smith
Journal:  Nat Rev Cardiol       Date:  2012-12-11       Impact factor: 32.419

8.  Cardiac resynchronization therapy is associated with a reduction in ICD therapies as it improves ventricular function.

Authors:  Enrique Galve; Gerard Oristrell; Gabriel Acosta; Aida Ribera-Solé; Àngel Moya-Mitjans; Ignacio Ferreira-González; Jordi Pérez-Rodon; David García-Dorado
Journal:  Clin Cardiol       Date:  2018-06-05       Impact factor: 2.882

9.  Cardiac Resynchronization and Defibrillator Therapy (CRT-D) or CRT Alone (CRT-P) in patients with dilated cardiomyopathy and heart failure without late gadolinium enhancement (LGE) cardiac magnetic resonance imaging (CMRI) high-risk markers - CRT-REALITY study - Study design and rationale.

Authors:  Milos Taborsky; Tomas Skala; Renata Aiglova; Marian Fedorco; Josef Kautzner; Tomas Jandik; Vlastimil Vancura; Ales Linhart; Martin Valek; Miloslav Novak; Petr Kala; Rostislav Polasek; Tomas Roubicek; Alexandr Schee; Gerhard Hindricks; Nikolaos Dagres; Robert Hatala; Jiri Jarkovsky
Journal:  Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub       Date:  2021-03-12       Impact factor: 1.245

10.  Causes-of-death analysis of patients with cardiac resynchronization therapy: an analysis of the CeRtiTuDe cohort study.

Authors:  Eloi Marijon; Christophe Leclercq; Kumar Narayanan; Serge Boveda; Didier Klug; Jonathan Lacaze-Gadonneix; Pascal Defaye; Sophie Jacob; Olivier Piot; Jean-Claude Deharo; Marie-Cecile Perier; Genevieve Mulak; Jean-Sylvain Hermida; Paul Milliez; Daniel Gras; Olivier Cesari; Françoise Hidden-Lucet; Frederic Anselme; Philippe Chevalier; Philippe Maury; Nicolas Sadoul; Pierre Bordachar; Serge Cazeau; Michel Chauvin; Jean-Philippe Empana; Xavier Jouven; Jean-Claude Daubert; Jean-Yves Le Heuzey
Journal:  Eur Heart J       Date:  2015-09-01       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.